Determination and/or following of High on-aspirin platelet reactivity (HARP) in CABG patients using the Verifynow Aspirin.

Determination and/or following of High on-aspirin platelet reactivity (HARP) in CABG patients using the Verifynow Aspirin. - HAPR in CABG patients

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON37275

Enrollment

Registered

2012-09-27

Start date

2013-01-07

Completion date

Unknown

Last updated

2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Aspirin resitance High on-aspirin platelet reactivity

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Elective pre-CABG patients (with during the CABG use of Heartlung machine) Use of preoperative Aspirin

Exclusion criteria

Exclusion criteria: Use of other platelets aggregation inhibiting medicines, NSAID'S, GPIIb/IIIa receptor antagonists, anticoagulants and/or heparines. (e.g., Dipyridamole, Acenocoumarol, Nadroparine, Plavix, etc.) Under-age patients and minors. Insufficient mastery of the Dutch or English to get wel informed. Intolerance to aspirin. Coagulation abnormalities, congenital platelets abnormalities and/or medication (non-aspirin) induced platelet abnormality

Design outcomes

Primary

Measure	Time frame
The primary endpoint is the moment that the number of 20 study subjects is reached and there have been five measurements of ARU with each patient.	—

Secondary

Measure	Time frame
-Average of ARU's per moment of measurement. -Difference in the ARU's per individual at different measuring moments. -The time of first postoperatively Aspirin gift. -Number of platelets at each measurement moment. -Number and amount of any per-and postoperative platelet transfusions. -Possible post-operative interventions (such as PCI, re-CABG, etc.) until the measuring time T5.	—

Countries

Netherlands

Outcome results